ENTA’s phase-2b trial in RSV misses primary endpoint: https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-topline-data-rsvp-study-edp-938 From the recent price action, it seems that this result may have been leaked.